<i>In vivo</i> selection of CMY-219 conferring resistance to ceftazidime-avibactam in an OXA-484-producing <i>E. coli</i> ST410
Resistance to ceftazidime-avibactam (CAZ-AVI) is a growing problem. This study describes the selection of CMY-219, a CMY-42 variant (G156D), conferring resistance to CAZ-AVI in an OXA-484-producing <i>Escherichia coli</i> ST410 after treatment. It raises concern about the risk of selection of CMY variants under CAZ-AVI exposure in ST410 and related clones, which commonly carry CMY-42, are prone to carbapenemase acquisition, and harbor modified PBP3.
Authors
- Delphine Girlich (ORCID: https://orcid.org/0000-0002-7698-2798)
- Inès Rezzoug (ORCID: https://orcid.org/0009-0006-9484-7932)
- Agnès B. Jousset (ORCID: https://orcid.org/0000-0002-8223-2213)
- Saoussen Oueslati (ORCID: https://orcid.org/0000-0001-5766-3831)
- Rémy A. Bonnin (ORCID: https://orcid.org/0000-0002-2307-3232)
- L Dortet
- Anne Delaval
- Cécile Emeraud (ORCID: https://orcid.org/0009-0006-3595-6434)
- Thierry Naas
- Caroline Guyot
- Aurélien Birer
Institutions
- Inserm (FR)
- Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR)
- Université Paris-Saclay (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- CEA Paris-Saclay (FR)
- Infectious Disease Models and Innovative Therapies (FR)
- CNR de la Résistance aux Antibiotiques (FR)
- Groupe Hospitalier Intercommunal Le Raincy Montfermeil (FR)
- Comprehensive Clinical Research (US)
Publication Details
- Journal
- Antimicrobial Agents and Chemotherapy
- Published
- 2026-02-12
- DOI
- https://doi.org/10.1128/aac.01335-25
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 0.00